Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome
NCT ID: NCT02535611
Last Updated: 2020-10-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
47 participants
INTERVENTIONAL
2015-10-31
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems
NCT01261741
Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease
NCT00469456
Effect of Memantine on Cognitive Impairment in Patients With Epilepsy
NCT04417543
The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients
NCT00255086
Memantine for Agitation in Dementia
NCT00371059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Memantine
Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
Memantine
Beside the usual treatment for ischemic stroke this group will be treated by memantine.
Placebo
Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.
Placebo
Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
Memantine
Beside the usual treatment for ischemic stroke this group will be treated by memantine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmation of ischemic stroke in MCA territory by imaging.
* Accepted consent form
Exclusion Criteria
* Stage 4 -5 renal failure base on Acute Kidney Injury Network criteria
* Moderate to severe hepatic failure (Child-Pugh criteria, grade B and C)
* History of epilepsy
* History of dementia
* History of memantine use in recent 6 months
* Pregnancy or breastfeeding
* Severe drug adverse effects
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mazandaran University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nasim Tabrizi
Assistant professor of neurology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAZUMS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.